Abdominal pain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: abdominal pains compared with placebo (very low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)
The review found no eligible studies for this question.
2 findings from 1 review
Treatment‐related adverse effects · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes treatment‐related adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Treatment‐related adverse effects · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: gastrointestinal compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: severe infection · SSNS in children
Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).
1 finding from 1 review
Treatment‐related adverse effects · adults and children with sickle cell disease experiencing neuropathic pain
It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary hypertension
1 finding from 1 review
Withdrawals due to adverse events · adults with primary hypertension
First‐line beta‐blocker may leads to higher withdrawal due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary hypertension
1 finding from 1 review
Adverse effects: serious or other · adults with nasal haemorrhage (epistaxis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse effects (yes or no) · patients with subjective idiopathic tinnitus
2 findings from 1 review
Other adverse effects (yes or no) · patients with subjective idiopathic tinnitus
1 finding from 1 review
Adverse effects of pain treatment · Adolescents and adults undergoing orthodontic treatment
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of pain treatment · Adolescents/teenagers undergoing orthodontic treatment
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of pain treatment · Adolescents and adults undergoing orthodontic treatment
The review found no eligible studies for this question.
1 finding from 1 review
Nausea and vomiting · patients with acute asthma
ICS showed no clear difference in adverse effects ‐ nausea/vomiting compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · hypertension in adults with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · adults in sinus rhythm after cardioversion of atrial fibrillation
Propafenone probably leads to higher withdrawals due to adverse effects compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults in sinus rhythm after cardioversion of atrial fibrillation
Flecainide showed no clear difference in withdrawals due to adverse effects compared with placebo or no treatment (low certainty).
1 finding from 1 review